{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5"}]}],"title":"ADA positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8"}]}],"title":"ADA and NAb positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2"}]}],"title":"Specificity CD22 positive of ADA+/NAb+"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5"}]}],"title":"Specificity PE38 positive of ADA+/NAb+"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Participants with ADA positive, nAb positive, cluster of differentiation 22 (CD22) positive of ADA positive/NAb positive, and pseudomonas exotoxin 38 (PE38) positive of ADA positive/NAb positive to moxetumomab pasudotox at any visit are reported.","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"NUMBER","populationDescription":"Safety population included participants who received at least 1 dose of moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"Pre-infusion on Day 1 of Cycles 1, 2, 3, and 5; at the End of Treatment (4 to 6 weeks after the last dose; approximately 7 months)","title":"Percentage of Participants With Positive Anti-drug Antibodies (ADA), Neutralizing Anti-drug Antibodies (nAb) and Specificity (CD22 and PE38) Positive to Moxetumomab Pasudotox","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}